Last reviewed · How we verify
Neomycin B (FRAMYCETIN)
Neomycin B (generic name: FRAMYCETIN) is a framycetin drug. It is currently in Phase 3 development.
Neomycin B works by blocking the transient receptor potential cation channel subfamily V member 1, which is involved in various cellular processes.
Neomycin B is a small molecule antibiotic with various clinical applications, including the treatment of conditions such as poliomyelitis, vaginitis, hordeolum, osteomyelitis, and cataract. It is used in experimental vaccines, including the Sabin Inactivated Poliovirus Vaccine, and has been studied for its safety and immunogenicity in adults, children, and infants.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FRAMYCETIN |
|---|---|
| Drug class | framycetin |
| Target | Lecithin retinol acyltransferase, Menin, Transient receptor potential cation channel subfamily V member 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Imagine your cells have special channels that help control the flow of important molecules. Neomycin B blocks these channels, which can help reduce inflammation and other symptoms. This can be beneficial for people with certain conditions, but it's essential to understand how it works and its potential effects on the body.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neomycin B CI brief — competitive landscape report
- Neomycin B updates RSS · CI watch RSS
Frequently asked questions about Neomycin B
What is Neomycin B?
How does Neomycin B work?
What is the generic name of Neomycin B?
What drug class is Neomycin B in?
What development phase is Neomycin B in?
What does Neomycin B target?
Related
- Drug class: All framycetin drugs
- Target: All drugs targeting Lecithin retinol acyltransferase, Menin, Transient receptor potential cation channel subfamily V member 1
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing